Longevity Medical Institute launches intranasal regenerative neurology platform

Longevity Medical Institute in San José del Cabo, Mexico, has launched a regenerative neurology program that uses an intranasal delivery platform to move therapies toward the brain without a lumbar puncture. The institute says the approach expands treatment options for selected neurological conditions alongside its existing intrathecal and other regenerative services.

Why it matters: - The new platform gives Longevity Medical Institute another route for delivering regenerative therapies to patients with neurological disorders. - The intranasal approach is designed as a less invasive alternative to intrathecal administration, which requires a lumbar puncture. - The launch adds to a broader neurological program that already includes intravenous therapies, advanced imaging and physician-guided care.

What happened: - Longevity Medical Institute announced the launch of its Regenerative Neurological Therapy Program on July 23, 2026, in San José del Cabo, Baja California Sur, Mexico. - The program features an intranasal delivery platform intended to transport regenerative therapies toward the brain through the nasal cavity. - Dr. Kirk Sanford, founder and CEO of Longevity Medical Institute, said the platform expands treatment personalization and gives physicians another administration option based on diagnosis, clinical findings and treatment goals.

The details: - The technology targets the upper nasal cavity near the olfactory region instead of relying on a conventional spray pump that deposits most material in the lower nasal passages. - The delivery system uses an electronically controlled nebulizer that creates microscopic aerosol droplets and releases them gradually over several minutes. - The controlled delivery is designed to increase contact time in the olfactory region, reduce medication loss into the throat and improve delivery consistency. - The institute says the platform is used exclusively for regenerative therapies, including mesenchymal stem cells, MSC-derived exosomes and selected therapeutic peptides. - Treatment recommendations are made after a multidisciplinary neurological evaluation that may include advanced imaging, laboratory testing, neurological examination and review of medical history. - Human clinical research on MSCs and MSC-derived exosomes has reported encouraging findings in ischemic stroke, multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, Parkinson’s disease, Alzheimer’s disease, traumatic brain injury, cerebral palsy and other neurodegenerative disorders. - Published studies have reported a favorable safety profile while exploring possible benefits in neurological function, disease stabilization, walking ability, cognitive performance, quality of life and neuroinflammation. - The institute says its neurological program also includes intravenous regenerative therapies, intrathecal administration performed in its fully licensed operating room when indicated, hyperbaric oxygen therapy, advanced neurological imaging and multidisciplinary physician care. - Longevity Medical Institute says treatment recommendations are based on physician evaluation, published scientific evidence, patient-specific factors and clinical judgment. - The institute says larger randomized clinical trials are still needed to identify which patients are most likely to benefit and how durable treatment responses may be.

Between the lines: - The launch reflects a push to make regenerative neurology less invasive while keeping intrathecal therapy available for cases where physicians think it is the better fit. - The use of an electronically controlled nebulizer suggests the institute is aiming for more precise delivery than standard nasal sprays can provide. - The emphasis on published human data and individualized evaluation signals a cautious clinical positioning, not a claim of a universal treatment.

What's next: - Longevity Medical Institute plans to continue using the new platform within its broader regenerative neurology program. - The institute points to ongoing clinical research as the main path for determining which patients benefit most and how long effects last. - More information about the program is available here.